SAB Biotherapeutics (SABS) Stock: Buy, Sell, or Hold?
SABS - SAB Biotherapeutics, Inc. Common Stock
$2.98
-0.08 (-2.61%)
▼
5d:
-9.42%
30d:
-20.53%
90d:
-23.98%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 13, 2026
Get Alerted When SABS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: SABS shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: SABS shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: SABS is currently trading at $2.98, which is considered oversold relative to its 30-day fair value range of $3.36 to $3.75.
Technical Outlook: Technically, SABS is in a downtrend. The price is currently testing key support at $2.96. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SABS scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.64 (+290.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SABS is in a downtrend. The price is currently testing key support at $2.96. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SABS scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.64 (+290.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.36 -
$3.75
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 290.5% below Wall St target ($11.64)
- WARNING: Composite score 35/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.36 -
$3.75
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.96
Resistance Level
$3.56
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.12
Wall Street Target
$11.64
(+290.5%)
Revenue Growth (YoY)
-62.4%
Earnings Growth (YoY)
-60.0%
Share & Embed Analysis
Last updated: October 03, 2026 1:46 PM ET
Data refreshes hourly during market hours. Next update: 2:46 PM
Data refreshes hourly during market hours. Next update: 2:46 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SABS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 71 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$28 | 53 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 58 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$52 | 66 BUY |
